Samsca (Tolvaptan) Patent Expiration, LOE Window & CMS Spending
Samsca (Tolvaptan) by Otsuka Pharmaceutical: FDA Orange Book core substance LOE 2026-09-01 (last listed 2030-04-07), 9 AB generics, $9.4M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Otsuka Pharmaceutical |
| FDA Application & Pathway | N022275 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-09-01 |
| Last Listed Patent or Exclusivity Date | 2030-04-07 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $9.4M |
| 2024 Medicare Part D Spend | $8.7M |
| 2024 Medicaid Spend | $633K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.